{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:46:40Z","timestamp":1762505200336},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1038\/ncpneph0362","type":"journal-article","created":{"date-parts":[[2006,12,20]],"date-time":"2006-12-20T15:35:22Z","timestamp":1166628922000},"page":"42-49","source":"Crossref","is-referenced-by-count":45,"title":["Mechanisms of Disease: the role of aldosterone in kidney damage and clinical benefits of its blockade"],"prefix":"10.1038","volume":"3","author":[{"given":"Lucia Del","family":"Vecchio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirella","family":"Procaccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Vigan\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Cusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFncpneph0362_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","volume":"135","author":"TH Jafar","year":"2001","unstructured":"Jafar TH et al. (2001) Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med 135: 73\u201387","journal-title":"Ann Intern Med"},{"key":"BFncpneph0362_CR2","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861\u2013869","journal-title":"N Engl J Med"},{"key":"BFncpneph0362_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ et al. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851\u2013860","journal-title":"N Engl J Med"},{"key":"BFncpneph0362_CR4","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S0140-6736(52)91551-1","volume":"2","author":"SA Simpson","year":"1952","unstructured":"Simpson SA et al. (1952) Secretion of a salt-retaining hormone by the mammalian adrenal cortex. Lancet 2: 226\u2013228","journal-title":"Lancet"},{"key":"BFncpneph0362_CR5","first-page":"2797","volume":"81","author":"Y Takeda","year":"1996","unstructured":"Takeda Y et al. (1996) Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 81: 2797\u20132800","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpneph0362_CR6","doi-asserted-by":"crossref","first-page":"24316","DOI":"10.1016\/S0021-9258(19)51084-5","volume":"269","author":"H Hatakeyama","year":"1994","unstructured":"Hatakeyama H et al. (1994) Vascular aldosterone: biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 269: 24316\u201324320","journal-title":"J Biol Chem"},{"key":"BFncpneph0362_CR7","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.1210\/en.2004-0081","volume":"145","author":"N Ahmad","year":"2004","unstructured":"Ahmad N et al. (2004) Do human vascular endothelial cells produce aldosterone? Endocrinology 145: 3626\u20133629","journal-title":"Endocrinology"},{"key":"BFncpneph0362_CR8","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.1074\/jbc.273.9.4883","volume":"273","author":"JS Silvestre","year":"1998","unstructured":"Silvestre JS et al. (1998) Myocardial production of aldosterone and corticosterone in the rat: physiological regulation. J Biol Chem 273: 4883\u20134891","journal-title":"J Biol Chem"},{"key":"BFncpneph0362_CR9","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1161\/01.CIR.0000142858.44680.27","volume":"110","author":"A Garnier","year":"2004","unstructured":"Garnier A et al. (2004) Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 110: 1819\u20131825","journal-title":"Circulation"},{"key":"BFncpneph0362_CR10","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.1210\/en.2005-0370","volume":"146","author":"P Ye","year":"2005","unstructured":"Ye P et al. (2005) The aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) genes are not expressed in the rat heart. Endocrinology 146: 5287\u20135293","journal-title":"Endocrinology"},{"key":"BFncpneph0362_CR11","first-page":"E342","volume":"288","author":"EP Gomez-Sanchez","year":"2005","unstructured":"Gomez-Sanchez EP et al. (2005) Is aldosterone synthesized within the rat brain? Am J Physiol Endocrinol Metab 288: E342\u2013E346","journal-title":"Metab"},{"key":"BFncpneph0362_CR12","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1161\/01.HYP.0000175814.18550.c0","volume":"46","author":"C Xue","year":"2005","unstructured":"Xue C et al. (2005) Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor. Hypertension 46: 584\u2013590","journal-title":"Hypertension"},{"key":"BFncpneph0362_CR13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jsbmb.2005.03.005","volume":"96","author":"T Nishikawa","year":"2005","unstructured":"Nishikawa T et al. (2005) Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL). J Steroid Biochem Mol Biol 96: 309\u2013316","journal-title":"J Steroid Biochem Mol Biol"},{"key":"BFncpneph0362_CR14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/00041552-200403000-00007","volume":"13","author":"EP Gomez-Sanchez","year":"2004","unstructured":"Gomez-Sanchez EP (2004) Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease. Curr Opin Nephrol Hypertens 13: 191\u2013196","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"BFncpneph0362_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1161\/01.CIR.92.2.175","volume":"92","author":"M Lombes","year":"1995","unstructured":"Lombes M et al. (1995) Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 92: 175\u2013182","journal-title":"Circulation"},{"key":"BFncpneph0362_CR16","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1006\/bbrc.2001.4275","volume":"280","author":"N Golestaneh","year":"2001","unstructured":"Golestaneh N et al. (2001) Mineralocorticoid receptor-mediated signaling regulates the ion gated sodium channel in vascular endothelial cells and requires an intact cytoskeleton. Biochem Biophys Res 280: 1300\u20131306","journal-title":"Biochem Biophys Res"},{"key":"BFncpneph0362_CR17","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1161\/01.RES.0000106135.02935.E1","volume":"93","author":"TR Uhrenholt","year":"2003","unstructured":"Uhrenholt TR et al. (2003) Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone. Circ Res 93: 1258\u20131266","journal-title":"Circ Res"},{"key":"BFncpneph0362_CR18","first-page":"F781","volume":"264","author":"KM Todd-Turla","year":"1993","unstructured":"Todd-Turla KM et al. (1993) Distribution of mineralocorticoid and glucocorticoid receptor mRNA along the nephron. Am J Physiol 264: F781\u2013F791","journal-title":"Am J Physiol"},{"key":"BFncpneph0362_CR19","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1161\/01.HYP.0000154681.38944.9a","volume":"45","author":"A Nishiyama","year":"2005","unstructured":"Nishiyama A et al. (2005) Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension 45: 710\u2013716","journal-title":"Hypertension"},{"key":"BFncpneph0362_CR20","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/01.HYP.0000174593.88899.68","volume":"46","author":"Y Nagai","year":"2005","unstructured":"Nagai Y et al. (2005) Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1\/2 in rat renal fibroblasts. Hypertension 46: 1039\u20131045","journal-title":"Hypertension"},{"key":"BFncpneph0362_CR21","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/01.HYP.0000111138.78714.1a","volume":"43","author":"S Arima","year":"2004","unstructured":"Arima S et al. (2004) Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension 43: 352\u2013357","journal-title":"Hypertension"},{"key":"BFncpneph0362_CR22","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1161\/01.CIR.0000093188.53554.44","volume":"108","author":"SL Liu","year":"2003","unstructured":"Liu SL et al. (2003) Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 108: 2400\u20132406","journal-title":"Circulation"},{"key":"BFncpneph0362_CR23","first-page":"893","volume":"120","author":"CG Brilla","year":"1992","unstructured":"Brilla CG et al. (1992) Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 120: 893\u2013901","journal-title":"J Lab Clin Med"},{"key":"BFncpneph0362_CR24","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1210\/en.2002-220926","volume":"144","author":"MJ Young","year":"2003","unstructured":"Young MJ et al. (2003) Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation. Endocrinology 144: 1121\u20131125","journal-title":"Endocrinology"},{"key":"BFncpneph0362_CR25","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0002-9440(10)64454-9","volume":"161","author":"Y Sun","year":"2002","unstructured":"Sun Y et al. (2002) Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 161: 1773\u20131781","journal-title":"Am J Pathol"},{"key":"BFncpneph0362_CR26","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709\u2013717","journal-title":"N Engl J Med"},{"key":"BFncpneph0362_CR27","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309\u20131321","journal-title":"N Engl J Med"},{"key":"BFncpneph0362_CR28","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/ki.1992.45","volume":"41","author":"ZY Quan","year":"1992","unstructured":"Quan ZY et al. (1992) Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int 41: 326\u2013333","journal-title":"Kidney Int"},{"key":"BFncpneph0362_CR29","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1172\/JCI118867","volume":"98","author":"EL Greene","year":"1996","unstructured":"Greene EL et al. (1996) Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 98: 1063\u20131068","journal-title":"J Clin Invest"},{"key":"BFncpneph0362_CR30","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1681\/ASN.2004090804","volume":"16","author":"JC Aldigier","year":"2005","unstructured":"Aldigier JC et al. (2005) Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 16: 3306\u20133314","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0362_CR31","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1046\/j.1523-1755.1998.00208.x","volume":"54","author":"W Linz","year":"1998","unstructured":"Linz W et al. (1998) Nephroprotection by long-term ACE inhibition with ramipril in spontaneously hypertensive stroke prone rats. Kidney Int 54: 2037\u20132044","journal-title":"Kidney Int"},{"key":"BFncpneph0362_CR32","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","volume":"31","author":"R Rocha","year":"1998","unstructured":"Rocha R et al. (1998) Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31: 451\u2013458","journal-title":"Hypertension"},{"key":"BFncpneph0362_CR33","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","volume":"33","author":"R Rocha","year":"1999","unstructured":"Rocha R et al. (1999) Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33: 232\u2013237","journal-title":"Hypertension"},{"key":"BFncpneph0362_CR34","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","volume":"141","author":"R Rocha","year":"2000","unstructured":"Rocha R et al. (2000) Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141: 3871\u20133878","journal-title":"Endocrinology"},{"key":"BFncpneph0362_CR35","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1161\/01.HYP.0000222003.28517.99","volume":"47","author":"M Nagase","year":"2006","unstructured":"Nagase M et al. (2006) Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 47: 1084\u20131093","journal-title":"Hypertension"},{"key":"BFncpneph0362_CR36","first-page":"F286","volume":"264","author":"M Horiuchi","year":"1993","unstructured":"Horiuchi M et al. (1993) Characterization of renal aldosterone receptors in genetically hypertensive rats. Am J Physiol 264: F286\u2013F291","journal-title":"Am J Physiol"},{"key":"BFncpneph0362_CR37","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/j.1523-1755.2004.00913.x","volume":"66","author":"G Fujisawa","year":"2004","unstructured":"Fujisawa G et al. (2004) Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 66: 1493\u20131502","journal-title":"Kidney Int"},{"key":"BFncpneph0362_CR38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/sj.ki.5000438","volume":"70","author":"KH Han","year":"2006","unstructured":"Han KH et al. (2006) Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int 70: 111\u2013120","journal-title":"Kidney Int"},{"key":"BFncpneph0362_CR39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1046\/j.1523-1755.2003.00707.x","volume":"63","author":"I Feria","year":"2003","unstructured":"Feria I et al. (2003) Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 63: 43\u201352","journal-title":"Kidney Int"},{"key":"BFncpneph0362_CR40","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1046\/j.1523-1755.2000.00277.x","volume":"58","author":"NJ Brown","year":"2000","unstructured":"Brown NJ et al. (2000) Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58: 1219\u20131227","journal-title":"Kidney Int"},{"key":"BFncpneph0362_CR41","doi-asserted-by":"publisher","first-page":"F1059","DOI":"10.1152\/ajprenal.00202.2003","volume":"286","author":"I Juknevicius","year":"2004","unstructured":"Juknevicius I et al. (2004) Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol Renal Physiol 286: F1059\u2013F1062","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFncpneph0362_CR42","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1161\/01.HYP.0000118519.66430.22","volume":"43","author":"A Nishiyama","year":"2004","unstructured":"Nishiyama A et al. (2004) Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone\/salt-induced hypertensive rats. Hypertension 43: 841\u2013848","journal-title":"Hypertension"},{"key":"BFncpneph0362_CR43","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1681\/ASN.2005040390","volume":"16","author":"K Miyata","year":"2005","unstructured":"Miyata K et al. (2005) Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 16: 2906\u20132912","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0362_CR44","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","volume":"63","author":"ER Blasi","year":"2003","unstructured":"Blasi ER et al. (2003) Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63: 1791\u20131800","journal-title":"Kidney Int"},{"key":"BFncpneph0362_CR45","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/sj.ki.5000201","volume":"69","author":"J Ma","year":"2006","unstructured":"Ma J et al. (2006) Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int 69: 1064\u20131072","journal-title":"Kidney Int"},{"key":"BFncpneph0362_CR46","first-page":"3","volume":"45","author":"JW Conn","year":"1955","unstructured":"Conn JW (1955) Presidential address. Part II: Primary hyperaldosteronism: a new clinical syndrome. J Lab Clin Med 45: 3\u201317","journal-title":"J Lab Clin Med"},{"key":"BFncpneph0362_CR47","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0002-9610(64)90252-1","volume":"107","author":"JW Conn","year":"1964","unstructured":"Conn JW et al. (1964) Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 107: 159\u2013172","journal-title":"Am J Surg"},{"key":"BFncpneph0362_CR48","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1681\/ASN.2004100878","volume":"16","author":"J Ribstein","year":"2005","unstructured":"Ribstein J et al. (2005) Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol 16: 1320\u20131325","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0362_CR49","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","volume":"295","author":"LA Sechi","year":"2006","unstructured":"Sechi LA et al. (2006) Long-term renal outcomes in patients with primary aldosteronism. JAMA 295: 2638\u20132645","journal-title":"JAMA"},{"key":"BFncpneph0362_CR50","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJM200109203451215","volume":"345","author":"A Chrysostomou","year":"2001","unstructured":"Chrysostomou A et al. (2001) Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 345: 925\u2013926","journal-title":"N Engl J Med"},{"key":"BFncpneph0362_CR51","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","volume":"41","author":"A Sato","year":"2003","unstructured":"Sato A et al. (2003) Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41: 64\u201368","journal-title":"Hypertension"},{"key":"BFncpneph0362_CR52","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.amjhyper.2004.06.029","volume":"18","author":"A Sato","year":"2005","unstructured":"Sato A et al. (2005) Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 18: 44\u201349","journal-title":"Am J Hypertens"},{"key":"BFncpneph0362_CR53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1053\/j.ajkd.2005.03.007","volume":"46","author":"S Bianchi","year":"2005","unstructured":"Bianchi S et al. (2005) Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 46: 45\u201351","journal-title":"Am J Kidney Dis"},{"key":"BFncpneph0362_CR54","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","volume":"68","author":"KJ Schjoedt","year":"2005","unstructured":"Schjoedt KJ et al. (2005) Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 68: 2829\u20132836","journal-title":"Kidney Int"},{"key":"BFncpneph0362_CR55","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/sj.ki.5001580","volume":"70","author":"KJ Schjoedt","year":"2006","unstructured":"Schjoedt KJ et al. (2006) Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 70: 536\u2013542","journal-title":"Kidney Int"},{"key":"BFncpneph0362_CR56","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/j.1464-5491.2004.01194.x","volume":"21","author":"R Rachmani","year":"2004","unstructured":"Rachmani R et al. (2004) The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 21: 471\u2013475","journal-title":"Diabet Med"},{"key":"BFncpneph0362_CR57","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1210\/jc.2005-1718","volume":"91","author":"K Takebayashi","year":"2006","unstructured":"Takebayashi K et al. (2006) Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 91: 2214\u20132217","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Nature Clinical Practice Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0362.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0362","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0362.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:15:51Z","timestamp":1684440951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpneph0362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["BFncpneph0362"],"URL":"https:\/\/doi.org\/10.1038\/ncpneph0362","relation":{},"ISSN":["1745-8323","1745-8331"],"issn-type":[{"value":"1745-8323","type":"print"},{"value":"1745-8331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}